Popular Trials
TLR8 Agonist
Selgantolimod for Chronic Hepatitis B and HIV
This trial tests a pill called Selgantolimod in patients with chronic hepatitis B and HIV who have been on antiviral therapy for an extended period. The pill aims to activate the immune system to reduce the hepatitis B virus levels in their blood.
Antiviral
JNJ-73763989 + Antivirals for Hepatitis B and D Co-Infection
This trial is testing a new drug called JNJ-73763989 combined with an existing medication to treat hepatitis D virus (HDV). The goal is to see if this combination works better than the current treatment alone. The new drug is expected to enhance the effectiveness of the existing medication.
Bcl-2 Inhibitor
Navitoclax + Sorafenib for Cancer
This trial is testing navitoclax and sorafenib tosylate in patients whose solid tumors have returned or don't respond to treatment. The drugs aim to stop cancer growth by blocking essential enzymes. Sorafenib has shown effectiveness in several cancers. The study will determine the best dose and monitor side effects.
Vaccine
Hepatitis B Vaccine for Hepatitis B
The aims of this study are to determine: 1. the degree of immunity against hepatitis B, 2. factors associated with immunity against hepatitis B, 3. if the amount of antigen provided in a booster dose (used to measure the degree of immune memory) affects the body's response to the booster, and 4. if the age at which the vaccination was initiated during infancy affects duration of protection against hepatitis B among adolescents 16-19 years of age born in the United States who were immunized against hepatitis B as infants. These data will be important to evaluate the potential need for a possible booster dose of hepatitis B vaccine among adolescents. Study subjects eligible for enrollment will: * have blood drawn for baseline serologies * receive the hepatitis B booster dose (randomly determined to be either a 10 ug or 20 ug dose) * have blood drawn again 14 days later to determine if the booster dose has engendered an anamnestic response (a response attributed to prior immunity rather than a new response to the vaccine) The primary hypothesis is that the majority of young people will exhibit immune memory for hepatitis B in response to a booster dose of vaccine.
Cytokine
IFN-γ 1b for Hepatitis B
Open-label, prospective, two part study evaluating IFN-γ 1b at a dose of 200μg by subcutaneous injection every day either alone or in combination with Adefovir dipivoxil or Adefovir dipivoxil alone at a dose of 10mg QD in patients with chronic Hepatitis B.
Popular Filters
Trials for Chronic Hepatitis B Patients
Nucleos(t)ide Analogue
AB-729 + Pegylated Interferon for Chronic Hepatitis B
This trial is testing a new drug called AB-729 for patients with Chronic Hepatitis B. It is used along with existing treatments to lower virus levels, manage the virus, and boost the immune system.
NA therapy
Stopping Antiviral Therapy for Chronic Hepatitis B
This trial is for patients with the early antigen negative form of chronic hepatitis B who have been on antiviral drugs for at least 192 weeks. The trial offers the option to stop or continue treatment to see if there are any clinical differences and what the mechanisms and gene expression profiles are that correlate with the clinical course.
Nucleos(t)ide Analogues
NA treatment for Chronic Hepatitis B
This is a prospective randomized, open-label, phase IV clinical trial to learn the effects, good and/or bad, of discontinuing or continuing nucleos(t)ide analogue (NA) treatment for 72 weeks in participants with chronic hepatitis B infection whose immune system is controlling the amount of virus levels in the blood for at least 12 months of NA therapy. About 66 adult men and women will participate in this study from University Health Network which includes the Toronto Western Hospital for about 72 weeks.
Antisense Oligonucleotide
Bepirovirsen for Chronic Hepatitis B
This trial is testing bepirovirsen, a medication that aims to lower a key protein made by the hepatitis B virus. Bepirovirsen has shown reductions in viral components in cell culture and animal models. It targets patients with specific levels of this protein in their blood. The goal is to see if bepirovirsen can better control the infection compared to current treatments.
Trials for CHB Patients
Nucleos(t)ide Analogue
AB-729 + Pegylated Interferon for Chronic Hepatitis B
This trial is testing a new drug called AB-729 for patients with Chronic Hepatitis B. It is used along with existing treatments to lower virus levels, manage the virus, and boost the immune system.
NA therapy
Stopping Antiviral Therapy for Chronic Hepatitis B
This trial is for patients with the early antigen negative form of chronic hepatitis B who have been on antiviral drugs for at least 192 weeks. The trial offers the option to stop or continue treatment to see if there are any clinical differences and what the mechanisms and gene expression profiles are that correlate with the clinical course.
Nucleos(t)ide Analogues
NA treatment for Chronic Hepatitis B
This is a prospective randomized, open-label, phase IV clinical trial to learn the effects, good and/or bad, of discontinuing or continuing nucleos(t)ide analogue (NA) treatment for 72 weeks in participants with chronic hepatitis B infection whose immune system is controlling the amount of virus levels in the blood for at least 12 months of NA therapy. About 66 adult men and women will participate in this study from University Health Network which includes the Toronto Western Hospital for about 72 weeks.
Antisense Oligonucleotide
Bepirovirsen for Chronic Hepatitis B
This trial is testing bepirovirsen, a medication that aims to lower a key protein made by the hepatitis B virus. Bepirovirsen has shown reductions in viral components in cell culture and animal models. It targets patients with specific levels of this protein in their blood. The goal is to see if bepirovirsen can better control the infection compared to current treatments.
Phase 3 Trials
Nucleoside Reverse Transcriptase Inhibitor
Antiviral Therapy for Hepatitis B Transmission Prevention
This trial tests antiviral drugs to prevent hepatitis B transmission from mothers to babies. It focuses on high-risk pregnant women and their newborns in Africa. The drugs lower virus levels in mothers and protect babies until they are vaccinated. One of the drugs, Tenofovir disoproxil fumarate (TDF), has been studied for its ability to prevent the spread of hepatitis B from mothers to their babies.
Antisense Oligonucleotide
Bepirovirsen for Chronic Hepatitis B
This trial is testing bepirovirsen, a medication that aims to lower a key protein made by the hepatitis B virus. Bepirovirsen has shown reductions in viral components in cell culture and animal models. It targets patients with specific levels of this protein in their blood. The goal is to see if bepirovirsen can better control the infection compared to current treatments.
Antisense Oligonucleotide
Bepirovirsen for Chronic Hepatitis B
This trial is testing bepirovirsen, a medication that aims to lower a key protein made by the hepatitis B virus. Bepirovirsen has shown reductions in viral components in cell culture and animal models. It targets patients with specific levels of this protein in their blood. The goal is to see if bepirovirsen can better control the infection compared to current treatments.
Trials With No Placebo
Chemotherapy
MTL-CEBPA + Sorafenib for Liver Cancer
This trial is testing an experimental treatment (MTL-CEBPA) in combination with a standard of care treatment (sorafenib) in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
Rapid Screening for Hepatitis C & B
This trial aims to study the effectiveness of rapid screening methods in diagnosing viral hepatitis infections compared to traditional methods. The goal is to provide same-day results to improve diagnosis rates and help healthcare providers engage with
Frequently Asked Questions
Introduction to hepatitis b
What are the top hospitals conducting hepatitis b research?
In the ongoing fight against hepatitis b, several top hospitals are at the forefront of groundbreaking clinical trials. One such institution is the University of California, San Francisco (UCSF) located in vibrant San Francisco. UCSF currently has three active trials dedicated to hepatitis B, with a cumulative total of seven trials conducted over time. Their pioneering efforts began back in 1999 when they recorded their first trial for this condition.
Moving eastward to Aurora, Colorado, we find the University of Colorado Hospital CRS making significant contributions to hepatitis B research. With two active trials and a small but impactful history of three previous studies on this disease, this hospital continues to push boundaries since embarking on their first hepatitis B trial just last year in 2020.
Meanwhile, across the country in Washington D.C., Whitman-Walker Health CRS is also actively involved in fighting against hepatitis B with two ongoing clinical trials. Their commitment began recently as well when they initiated their first recorded trial for this condition alongside The Ponce de Leon Center CRS based in Atlanta and Northwestern University CRS located within Chicago both showcasing similar dedication by conducting hepatisisb related research through two active projects while having participation experience before once again since entering into field coincidingly only from 2020 onwards.
These hospitals play vital roles not only by offering hope to those affected by hepatitis B but also by pushing forward our understanding and treatment options for this serious liver infection that affects millions worldwide. Through these clinical trials conducted across various locations throughout the United States - from sunny San Francisco all the way to bustling Chicago - medical professionals are working diligently towards finding new treatments and ultimately striving for better outcomes for patients living with hepatitis B
Which are the best cities for hepatitis b clinical trials?
When it comes to hepatitis b clinical trials, several cities stand out as hubs for cutting-edge research. In New york, there are currently 17 active trials exploring treatments like Selgantolimod and HEPLISAV-B among others. San Francisco follows closely behind with 12 ongoing studies that investigate interventions such as stopping NA therapy and utilizing Selgantolimod. Honolulu in Hawaii also boasts 12 active trials focusing on Tenofovir Alafenamide and other potential breakthroughs. Lastly, Los Angeles and Houston both contribute to the advancement of hepatitis B research with their respective nine and eight active trials studying various treatment options. Through these dedicated efforts in multiple cities across the United States, researchers strive to improve outcomes for individuals affected by hepatitis B infection.
Which are the top treatments for hepatitis b being explored in clinical trials?
Exciting advancements are underway in the clinical trials exploring treatments for hepatitis b. Among the top contenders is GSK3228836, currently being tested in two active trials and with a total of six all-time hepatitis B trials since its introduction in 2020. Another promising option is JNJ-73763989, which has also gained traction with two ongoing trials and nine all-time hepatitis B studies since it was first listed in 2019. Additionally, Tenofovir Alafenamide shows promise as a treatment option with two active trials and an impressive tally of 18 all-time hepatitis B trials dating back to 2010. Lastly, keep an eye on bepirovirsen, a newcomer to the scene that has already initiated two active clinical trials after its listing in 2022. As research progresses further into these various investigational treatments, hope continues to grow for patients affected by hepatitis B worldwide.
What are the most recent clinical trials for hepatitis b?
Exciting developments in the field of hepatitis b research have brought forth promising clinical trials that may pave the way for improved treatment options. One such trial is Active, a Phase 2 study that aims to assess the efficacy and safety of a new intervention for hepatitis B. Additionally, Group 1a investigates the potential benefits of HepB mAb19 administered intravenously, with Phase 1 focusing on determining its safety profile. Another noteworthy trial is Selgantolimod, currently in Phase 2, which holds promise as a potential therapeutic agent against hepatitis B. The development and evaluation of these innovative treatments signify significant progress towards addressing this challenging condition and improving patient outcomes.
What hepatitis b clinical trials were recently completed?
Recently, several important clinical trials investigating potential treatments for hepatitis b have reached completion. In September 2021, GlaxoSmithKline concluded a trial studying the effectiveness of GSK3228836. Additionally, Nucorion Pharmaceuticals wrapped up their investigation into NCO-48 Fumarate 20 mg in January 2021. Another trial involving GSK3228836 by GlaxoSmithKline was completed in July 2020. Furthermore, Janssen Sciences Ireland UC completed their study on JNJ-73763989 back in August 2019. Finally, the University of Maryland conducted a trial exploring the benefits of B/F/TAF that finished in April 2019. These recent advancements mark significant progress towards improving treatments for hepatitis B and offer hope to those affected by this persistent virus.